ベイジーンに関するコメント

The market's expectation of a decline in future revenue performance could be keeping BeiGene's P/S ratio low. Despite potential for share price to match revenue if current course is maintained, the company's inferior revenue outlook may suggest limited future growth to investors.

BeiGene's cash surplus suggests safe debt management. However, future profitability will determine balance sheet strength. Despite being pre-profit, its revenue growth indicates potential profitability.

HBM gets health boost from drug licensing deals
December 22, 2023
2142.HK
1.56
(-2.5%)
The biopharma company has marked out a path to profitability by licensing its drug expertise and antibody platforms to partners such as Pfizer
Key Takeaways:
Nona Biosciences, a subsidiary of HBM Holdings, has struck a licensing-out deal with a Pfizer-owned biotech  for an initial sum of $53 million and milestone payments of up to $1.05 billion
HBM Holdin...